Welcome to our dedicated page for Citius Pharmaceuticals news (Ticker: CTXR), a resource for investors and traders seeking the latest updates and insights on Citius Pharmaceuticals stock.
Citius Pharmaceuticals Inc. (CTXR) delivers innovative therapies for critical care needs through its pipeline of novel oncology treatments and anti-infective solutions. This news hub provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic initiatives shaping the company's progress.
Access verified information about CTXR's FDA interactions, trial results for therapies like LYMPHIR™ and Mino-Lok®, and partnership announcements. Our curated collection ensures you stay informed about material events without promotional bias, supporting data-driven decision-making in this specialized biopharmaceutical sector.
Key updates include progress reports on late-stage clinical programs, manufacturing expansions, and peer-reviewed research publications. All content undergoes strict verification to maintain compliance with financial disclosure standards while preserving accessibility for both medical and investment audiences.
Bookmark this page for streamlined tracking of CTXR's advancements in targeted immunotherapies and critical care innovations. Combine regular monitoring with professional financial advice to maintain perspective on the company's evolving market position.
Citius Pharmaceuticals (NASDAQ: CTXR) has made significant progress in its Mino-Lok® Phase 3 clinical trial, now achieving 85 of the 92 events required for completion. Currently, 190 patients have been enrolled, with 16 patients actively receiving treatment or pending data review. The trial involves multiple centers across 35 sites in the U.S. and India. Mino-Lok® is an antibiotic lock solution aimed at salvaging catheters in patients suffering from catheter-related bloodstream infections (CRBSI/CLABSI). If approved, it would be the first FDA-approved treatment for this condition. The positive trajectory of this trial could lead to significant advancements in critical care and strengthen Citius’s market position.
Citius Pharmaceuticals (CTXR) announced the completion of patient enrollment in its Phase 2b clinical study of Halo-Lido (CITI-002), a topical formulation aimed at treating hemorrhoids. The study enrolled approximately 300 adults and its results are expected by the end of Q2 2023. This trial marks an important milestone as CITI-002 could become the first prescription product for hemorrhoids if approved by the FDA. The company aims to leverage these results to advance to a Phase 3 study, reflecting its belief in a significant market opportunity for a prescription hemorrhoid treatment.
Citius Pharmaceuticals (Nasdaq: CTXR) announced it will engage Maxim Group LLC as a financial advisor for its subsidiary, Citius Acquisition Corp. Inc. This initiative aims to spin off its oncology asset, I/ONTAK, into a publicly-traded company. The FDA is reviewing the biologics license application (BLA) for I/ONTAK, targeting a decision by July 28, 2023. Citius intends to maximize I/ONTAK’s value while maintaining its trading status on Nasdaq. Any transactions will be subject to board and regulatory approvals. Investors are cautioned that the completion of these transactions is uncertain and is dependent on various conditions.
FAQ
What is the current stock price of Citius Pharmaceuticals (CTXR)?
What is the market cap of Citius Pharmaceuticals (CTXR)?
